Loading...
•
Mar 31, 2021
Adaptive Biotechnologies Q1 2021 Earnings Report
Adaptive Biotechnologies reported an 84% increase in revenue year over year, driven by growth in both sequencing and development revenue categories.
Key Takeaways
Adaptive Biotechnologies reported a strong start to the year with revenue increasing 84% year over year. The company's clonoSEQ clinical sequencing volume grew 35% versus the prior year. They also recognized $7.0 million in MRD regulatory milestones.
Revenue of $38.4 million for the first quarter 2021, representing an 84% increase from the first quarter 2020
clonoSEQ clinical sequencing volume for the first quarter 2021 grew 35% versus prior year
Recognized $7.0 million in MRD regulatory milestones resulting from two biopharmaceutical partners who used data from our MRD assay to support their respective U.S. Food and Drug Administration (FDA) drug approvals
Received Emergency Use Authorization (EUA) from FDA for T-Detect™ COVID to confirm recent or prior COVID-19 infection
Forward Guidance
Adaptive Biotechnologies expects full year 2021 revenue to be in the range of $145 million to $155 million, representing 52% growth at the mid-point of the range over full year 2020 revenue.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...